Drugs: cardiovascular system

Citations 1-10 of 429 total displayed.

Therapeutics
Review: diabetes is not a coronary disease equivalent

Michael E Farkouh
Evid. Based Med. 2009; 14: 136-137. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Screening for CAD in asymptomatic patients with type 2 diabetes did not reduce risk of cardiac events

Evid. Based Med. 2009; 14: 137. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes

Vivian Fonseca
Evid. Based Med. 2009; 14: 139. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation

Andrew Dunn
Evid. Based Med. 2009; 14: 140. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Review: combining 2 classes of blood pressure–lowering drugs has an approximately additive effect on systolic blood pressure

Alena Shantsila, Gregory Y H Lip
Evid. Based Med. 2009; 14: 142. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Review: continuous positive airway pressure devices are effective and cost-effective for obstructive sleep apnoea

Arjun B Chatterjee
Evid. Based Med. 2009; 14: 143. [Extract] [Full text] [PDF] [Request Permissions]  

Aetiology
BMI <22.5 and >25 predicted higher overall mortality in adults

Lawrence J Cheskin, Stephen J Gange
Evid. Based Med. 2009; 14: 152. [Extract] [Full text] [PDF] [Request Permissions]  

Aetiology
Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Christopher B Granger
Evid. Based Med. 2009; 14: 154. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Intensive primary care treatment reduced cardiovascular risk factors in screen-detected type 2 diabetes

C Raina Elley, Tim Kenealy
Evid. Based Med. 2009; 14: 108. [Extract] [Full text] [PDF] [Request Permissions]  

Therapeutics
Rofecoxib increased risk of CV events in patients with history of colorectal adenomas 1 year after stopping treatment

Francis K L Chan
Evid. Based Med. 2009; 14: 111. [Extract] [Full text] [PDF] [Request Permissions]